European Psychiatry - Volume 33 - March 2016

76 / 812

Available online at
ScienceDirect
24th European Congress of Psychiatry
Free communications
Addictive behaviours
FC01
“Dual disorder with drugs”:
Comparison of two French databases
A. Batisse ∗, N. Taright , C. Chevallier , M. Marillier ,
S. Djezzar
1 Groupe hospitalier Lariboisière/Fernand-Widal/Saint-Louis,
CEIP-Addictovigilance, Paris, France
2 AP–HP, Département d’information médicale, Paris, France
∗ Corresponding author.
Context Dual diagnosis (substance used disorders (SUD) and
mental illness) represents 3% of general population. Among United
States population, 42.3% of SUD patients have psychiatric troubles
(without tobacco). Moreover, SUD can concern all psychoactive
substances (PAS) or illicit PAS only named “dual disorder with
drugs” (DDD).
Methods A quantitative analysis of DDD data from January 2013
to July 2014 of two epidemiological tools has been performed:
PMSI database (Programme Médicalisé des Systeme d’Information)
hospital discharge data is made up of data providing medical infor-
mation for all patients discharged in Paris public hospital system
(AP–HP) and NOT’S is a vigilance database of spontaneous NOTifi-
cations of drug abuse and dependence. We propose a descriptive
analysis of DDD in Paris metropolitan area.
Results With PMSI, 9.2% of SUD inpatients (n = 617) have DDD,
with mean age of 46 years (62% of men). In comparison, NOT’S
reports 36% of SUD with DDD (n = 302) with mean age of 39.5 years
(68% of men). Suicide attempt is also listed and reach 23% of cases.
Conclusion These two databases show the difficulty of
DDD diagnosis with the discordance in results. DDD miss in PMSI
database since addictovigilance database shows a first prevalence
of DDD. Despite the high rates of DDD, the problem is often under
diagnosed by clinicians practising. It is also important to promote
the collaboration among health care workers (addictologist and
psychiatrist) because these patients require intensive mental and
substance abuse care.
Table 1
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC02
25I-NBOMe: The legal LSD
I. Ezquiaga ∗, M. Grifell , L. Galindo , L. Martínez ,
Á. Palma , P. Quintana , M. Ventura , E. Ribera , L. Pujol ,
I. Fornís , M. Torrens , M. Farré
1 Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar,
Psychiatry, Barcelona, Spain
2 Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, IMIM,
Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain
3 Energy Control, Asociación Bienestar y Desarrollo, Energy Control,
Primary Care, Barcelona, Spain
4 Energy Control, Asociación Bienestar y Desarrollo, Energy Control,
Barcelona, Spain
5 Hospital Universitari Germans Trías i Pujol, IGTP, Universitat
Autònoma de Barcelona, Psychiatry, Barcelona, Spain
∗ Corresponding author.
Introduction Novel psychoactive substances (NPS) use is progres-
sively increasing year on year. A new group of phenethylamines
sold as legal stimulants and hallucinogens is being reported
increasingly since 2012. Within this group, 25I-NBOMe is an out-
standing substance with powerful effects and high affinity with
the serotonin 2a (5HT2a) receptor. Several toxicity cases have been
reported so far.
Objectives To describe the presence of 25I-NBOMe and its charac-
teristics in samples delivered to Energy Control from 2009 to 2015
in Spain.
0924-9338/$ – see front matter